P-55 FIRST EVALUATION ALBI SCORE COULD BE A TOOL FOR RISK STRATIFICATION OF HCC DEVELOPMENT IN PATIENTS WITH CHRONIC HEPATITIS C AND CIRRHOSIS Article Swipe
Cláudia Maccali
,
Isabel Veloso Alves Pereira
,
Lisa R. C. Saud
,
Regiane Saraiva de Souza Melo Alencar
,
Arthur In Oliveira
,
José Tadeu Stefano
,
Aline Lopes Chagas
,
Mário Guimarães Pessôa
,
Cláudia P. Oliveira
·
YOU?
·
· 2024
· Open Access
·
· DOI: https://doi.org/10.1016/j.aohep.2024.101669
YOU?
·
· 2024
· Open Access
·
· DOI: https://doi.org/10.1016/j.aohep.2024.101669
Conflict of interest: No Introduction and Objectives: Hepatitis C virus (HCV) still is the leading cause of hepatocellular carcinoma (HCC) in Brazil, even after the new treatments with DAAs. HCC surveillance is recommended based on liver fibrosis, whereby patients with advanced fibrosis are suitable for screening. Therefore, there is a need for tools to improve risk stratification in this population. Our aim was to assess whether the ALBI score performed at first evaluation of patients with HCV-related cirrhosis could stratify the risk of developing HCC. Patients / Materials and Methods: This study included 108 patients with HCV-related cirrhosis evaluated in the outpatient units in Hospital de Clínicas da Faculdade de Medicina da Universidade de São Paulo, Brazil. Clinical data from the first evaluation and ALBI score with first the laboratory tests were used for the statistical analysis. The last follow-up was at the last HCC screening image in patients who did not develop HCC and at HCC diagnosis in those who did. The statistical analyses were performed using Jamovi software version 2.3.23. Results and Discussion: During follow-up, with a mean duration of 5.28 ± 4.72 years, 32 patients developed HCC. Patients who developed HCC had significantly lower albumin values (p=0.039) and a higher proportion of ALBI grade 2 (p=0.036) at the first outpatient assessment. Evaluating HCC risk over time by Kaplan-Meier, patients with ALBI grade 2 had a significantly higher risk of developing HCC than patients with ALBI grade 1 (p=0.019) when assessed at 1 year (17% vs. 8.2%), 2 years (29.3% vs. 15.4%), 5 years (40.9% vs. 21.4%) and 10 years (47.4% vs. 23.9%). Patients with ALBI grade 2 had a two-fold higher risk of developing HCC during follow-up (OR 2.27, 95%CI 1.12-4.59, p=0.023). Conclusions: Assessment of baseline ALBI score can improve HCC risk stratification in patients with HCV-related cirrhosis.
Related Topics
Concepts
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.1016/j.aohep.2024.101669
- OA Status
- gold
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4405120653
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4405120653Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1016/j.aohep.2024.101669Digital Object Identifier
- Title
-
P-55 FIRST EVALUATION ALBI SCORE COULD BE A TOOL FOR RISK STRATIFICATION OF HCC DEVELOPMENT IN PATIENTS WITH CHRONIC HEPATITIS C AND CIRRHOSISWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2024Year of publication
- Publication date
-
2024-12-01Full publication date if available
- Authors
-
Cláudia Maccali, Isabel Veloso Alves Pereira, Lisa R. C. Saud, Regiane Saraiva de Souza Melo Alencar, Arthur In Oliveira, José Tadeu Stefano, Aline Lopes Chagas, Mário Guimarães Pessôa, Cláudia P. OliveiraList of authors in order
- Landing page
-
https://doi.org/10.1016/j.aohep.2024.101669Publisher landing page
- Open access
-
YesWhether a free full text is available
- OA status
-
goldOpen access status per OpenAlex
- OA URL
-
https://doi.org/10.1016/j.aohep.2024.101669Direct OA link when available
- Concepts
-
Medicine, Cirrhosis, Risk stratification, Chronic hepatitis, Internal medicine, Gastroenterology, Virology, VirusTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
0Total citation count in OpenAlex
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4405120653 |
|---|---|
| doi | https://doi.org/10.1016/j.aohep.2024.101669 |
| ids.doi | https://doi.org/10.1016/j.aohep.2024.101669 |
| ids.openalex | https://openalex.org/W4405120653 |
| fwci | 0.0 |
| type | article |
| title | P-55 FIRST EVALUATION ALBI SCORE COULD BE A TOOL FOR RISK STRATIFICATION OF HCC DEVELOPMENT IN PATIENTS WITH CHRONIC HEPATITIS C AND CIRRHOSIS |
| biblio.issue | |
| biblio.volume | 29 |
| biblio.last_page | 101669 |
| biblio.first_page | 101669 |
| topics[0].id | https://openalex.org/T10151 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 0.9945999979972839 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2721 |
| topics[0].subfield.display_name | Hepatology |
| topics[0].display_name | Hepatitis C virus research |
| topics[1].id | https://openalex.org/T10351 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.9879999756813049 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2713 |
| topics[1].subfield.display_name | Epidemiology |
| topics[1].display_name | Liver Disease Diagnosis and Treatment |
| is_xpac | False |
| apc_list.value | 1500 |
| apc_list.currency | USD |
| apc_list.value_usd | 1500 |
| apc_paid.value | 1500 |
| apc_paid.currency | USD |
| apc_paid.value_usd | 1500 |
| concepts[0].id | https://openalex.org/C71924100 |
| concepts[0].level | 0 |
| concepts[0].score | 0.9596267342567444 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[0].display_name | Medicine |
| concepts[1].id | https://openalex.org/C2777214474 |
| concepts[1].level | 2 |
| concepts[1].score | 0.8493236303329468 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q147778 |
| concepts[1].display_name | Cirrhosis |
| concepts[2].id | https://openalex.org/C3020404979 |
| concepts[2].level | 2 |
| concepts[2].score | 0.7408891916275024 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q1058438 |
| concepts[2].display_name | Risk stratification |
| concepts[3].id | https://openalex.org/C3020491458 |
| concepts[3].level | 3 |
| concepts[3].score | 0.6873869895935059 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q131742 |
| concepts[3].display_name | Chronic hepatitis |
| concepts[4].id | https://openalex.org/C126322002 |
| concepts[4].level | 1 |
| concepts[4].score | 0.6334788799285889 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[4].display_name | Internal medicine |
| concepts[5].id | https://openalex.org/C90924648 |
| concepts[5].level | 1 |
| concepts[5].score | 0.5581150650978088 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q120569 |
| concepts[5].display_name | Gastroenterology |
| concepts[6].id | https://openalex.org/C159047783 |
| concepts[6].level | 1 |
| concepts[6].score | 0.13816708326339722 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q7215 |
| concepts[6].display_name | Virology |
| concepts[7].id | https://openalex.org/C2522874641 |
| concepts[7].level | 2 |
| concepts[7].score | 0.06539750099182129 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q808 |
| concepts[7].display_name | Virus |
| keywords[0].id | https://openalex.org/keywords/medicine |
| keywords[0].score | 0.9596267342567444 |
| keywords[0].display_name | Medicine |
| keywords[1].id | https://openalex.org/keywords/cirrhosis |
| keywords[1].score | 0.8493236303329468 |
| keywords[1].display_name | Cirrhosis |
| keywords[2].id | https://openalex.org/keywords/risk-stratification |
| keywords[2].score | 0.7408891916275024 |
| keywords[2].display_name | Risk stratification |
| keywords[3].id | https://openalex.org/keywords/chronic-hepatitis |
| keywords[3].score | 0.6873869895935059 |
| keywords[3].display_name | Chronic hepatitis |
| keywords[4].id | https://openalex.org/keywords/internal-medicine |
| keywords[4].score | 0.6334788799285889 |
| keywords[4].display_name | Internal medicine |
| keywords[5].id | https://openalex.org/keywords/gastroenterology |
| keywords[5].score | 0.5581150650978088 |
| keywords[5].display_name | Gastroenterology |
| keywords[6].id | https://openalex.org/keywords/virology |
| keywords[6].score | 0.13816708326339722 |
| keywords[6].display_name | Virology |
| keywords[7].id | https://openalex.org/keywords/virus |
| keywords[7].score | 0.06539750099182129 |
| keywords[7].display_name | Virus |
| language | en |
| locations[0].id | doi:10.1016/j.aohep.2024.101669 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S32516778 |
| locations[0].source.issn | 1665-2681, 2659-5982 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | True |
| locations[0].source.issn_l | 1665-2681 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | True |
| locations[0].source.display_name | Annals of Hepatology |
| locations[0].source.host_organization | https://openalex.org/P4310320990 |
| locations[0].source.host_organization_name | Elsevier BV |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310320990 |
| locations[0].source.host_organization_lineage_names | Elsevier BV |
| locations[0].license | cc-by-nc-nd |
| locations[0].pdf_url | |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | https://openalex.org/licenses/cc-by-nc-nd |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Annals of Hepatology |
| locations[0].landing_page_url | https://doi.org/10.1016/j.aohep.2024.101669 |
| locations[1].id | pmh:oai:doaj.org/article:5d23f59e71bd47039dc62db62ff003b8 |
| locations[1].is_oa | False |
| locations[1].source.id | https://openalex.org/S4306401280 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | DOAJ (DOAJ: Directory of Open Access Journals) |
| locations[1].source.host_organization | |
| locations[1].source.host_organization_name | |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | submittedVersion |
| locations[1].raw_type | article |
| locations[1].license_id | |
| locations[1].is_accepted | False |
| locations[1].is_published | False |
| locations[1].raw_source_name | Annals of Hepatology, Vol 29, Iss , Pp 101669- (2024) |
| locations[1].landing_page_url | https://doaj.org/article/5d23f59e71bd47039dc62db62ff003b8 |
| indexed_in | crossref, doaj |
| authorships[0].author.id | https://openalex.org/A5021976295 |
| authorships[0].author.orcid | https://orcid.org/0000-0002-0300-2066 |
| authorships[0].author.display_name | Cláudia Maccali |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Claudia Maccali |
| authorships[0].is_corresponding | False |
| authorships[1].author.id | https://openalex.org/A5059728844 |
| authorships[1].author.orcid | https://orcid.org/0000-0002-3439-1658 |
| authorships[1].author.display_name | Isabel Veloso Alves Pereira |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Isabel Veloso Pereira |
| authorships[1].is_corresponding | False |
| authorships[2].author.id | https://openalex.org/A5050983727 |
| authorships[2].author.orcid | |
| authorships[2].author.display_name | Lisa R. C. Saud |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Lisa RC Saud |
| authorships[2].is_corresponding | False |
| authorships[3].author.id | https://openalex.org/A5029509165 |
| authorships[3].author.orcid | https://orcid.org/0000-0002-6621-5253 |
| authorships[3].author.display_name | Regiane Saraiva de Souza Melo Alencar |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Regiane SSM Alencar |
| authorships[3].is_corresponding | False |
| authorships[4].author.id | https://openalex.org/A5101309305 |
| authorships[4].author.orcid | |
| authorships[4].author.display_name | Arthur In Oliveira |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Arthur IN Oliveira |
| authorships[4].is_corresponding | False |
| authorships[5].author.id | https://openalex.org/A5002519934 |
| authorships[5].author.orcid | https://orcid.org/0000-0002-0218-1920 |
| authorships[5].author.display_name | José Tadeu Stefano |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Jose Tadeu Stefano |
| authorships[5].is_corresponding | False |
| authorships[6].author.id | https://openalex.org/A5039495800 |
| authorships[6].author.orcid | https://orcid.org/0000-0002-7404-2540 |
| authorships[6].author.display_name | Aline Lopes Chagas |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | Aline L Chagas |
| authorships[6].is_corresponding | False |
| authorships[7].author.id | https://openalex.org/A5046603491 |
| authorships[7].author.orcid | https://orcid.org/0000-0002-0942-7348 |
| authorships[7].author.display_name | Mário Guimarães Pessôa |
| authorships[7].author_position | middle |
| authorships[7].raw_author_name | Mario G Pessoa |
| authorships[7].is_corresponding | False |
| authorships[8].author.id | https://openalex.org/A5072591143 |
| authorships[8].author.orcid | https://orcid.org/0000-0002-2848-417X |
| authorships[8].author.display_name | Cláudia P. Oliveira |
| authorships[8].author_position | last |
| authorships[8].raw_author_name | Claudia P Oliveira |
| authorships[8].is_corresponding | False |
| has_content.pdf | False |
| has_content.grobid_xml | False |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://doi.org/10.1016/j.aohep.2024.101669 |
| open_access.oa_status | gold |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | P-55 FIRST EVALUATION ALBI SCORE COULD BE A TOOL FOR RISK STRATIFICATION OF HCC DEVELOPMENT IN PATIENTS WITH CHRONIC HEPATITIS C AND CIRRHOSIS |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T10151 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 0.9945999979972839 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2721 |
| primary_topic.subfield.display_name | Hepatology |
| primary_topic.display_name | Hepatitis C virus research |
| related_works | https://openalex.org/W2381582913, https://openalex.org/W2431455317, https://openalex.org/W2360662173, https://openalex.org/W2169735879, https://openalex.org/W2417923641, https://openalex.org/W2921112476, https://openalex.org/W2367136502, https://openalex.org/W2393756952, https://openalex.org/W2336043001, https://openalex.org/W2393158688 |
| cited_by_count | 0 |
| locations_count | 2 |
| best_oa_location.id | doi:10.1016/j.aohep.2024.101669 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S32516778 |
| best_oa_location.source.issn | 1665-2681, 2659-5982 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | True |
| best_oa_location.source.issn_l | 1665-2681 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | True |
| best_oa_location.source.display_name | Annals of Hepatology |
| best_oa_location.source.host_organization | https://openalex.org/P4310320990 |
| best_oa_location.source.host_organization_name | Elsevier BV |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310320990 |
| best_oa_location.source.host_organization_lineage_names | Elsevier BV |
| best_oa_location.license | cc-by-nc-nd |
| best_oa_location.pdf_url | |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by-nc-nd |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | Annals of Hepatology |
| best_oa_location.landing_page_url | https://doi.org/10.1016/j.aohep.2024.101669 |
| primary_location.id | doi:10.1016/j.aohep.2024.101669 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S32516778 |
| primary_location.source.issn | 1665-2681, 2659-5982 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | True |
| primary_location.source.issn_l | 1665-2681 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | True |
| primary_location.source.display_name | Annals of Hepatology |
| primary_location.source.host_organization | https://openalex.org/P4310320990 |
| primary_location.source.host_organization_name | Elsevier BV |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310320990 |
| primary_location.source.host_organization_lineage_names | Elsevier BV |
| primary_location.license | cc-by-nc-nd |
| primary_location.pdf_url | |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | https://openalex.org/licenses/cc-by-nc-nd |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Annals of Hepatology |
| primary_location.landing_page_url | https://doi.org/10.1016/j.aohep.2024.101669 |
| publication_date | 2024-12-01 |
| publication_year | 2024 |
| referenced_works_count | 0 |
| abstract_inverted_index./ | 86 |
| abstract_inverted_index.1 | 239, 244 |
| abstract_inverted_index.2 | 207, 225, 249, 269 |
| abstract_inverted_index.5 | 254 |
| abstract_inverted_index.C | 8 |
| abstract_inverted_index.a | 49, 178, 201, 227, 271 |
| abstract_inverted_index.10 | 260 |
| abstract_inverted_index.32 | 186 |
| abstract_inverted_index.No | 3 |
| abstract_inverted_index.at | 70, 141, 155, 209, 243 |
| abstract_inverted_index.by | 219 |
| abstract_inverted_index.da | 107, 111 |
| abstract_inverted_index.de | 105, 109, 113 |
| abstract_inverted_index.in | 20, 57, 99, 103, 147, 158, 296 |
| abstract_inverted_index.is | 12, 31, 48 |
| abstract_inverted_index.of | 1, 16, 73, 82, 181, 204, 231, 275, 287 |
| abstract_inverted_index.on | 34 |
| abstract_inverted_index.to | 53, 63 |
| abstract_inverted_index.± | 183 |
| abstract_inverted_index.(OR | 280 |
| abstract_inverted_index.108 | 93 |
| abstract_inverted_index.HCC | 29, 144, 153, 156, 193, 215, 233, 277, 293 |
| abstract_inverted_index.Our | 60 |
| abstract_inverted_index.The | 137, 162 |
| abstract_inverted_index.aim | 61 |
| abstract_inverted_index.and | 5, 88, 123, 154, 173, 200, 259 |
| abstract_inverted_index.are | 42 |
| abstract_inverted_index.can | 291 |
| abstract_inverted_index.did | 150 |
| abstract_inverted_index.for | 44, 51, 133 |
| abstract_inverted_index.had | 194, 226, 270 |
| abstract_inverted_index.new | 25 |
| abstract_inverted_index.not | 151 |
| abstract_inverted_index.the | 13, 24, 66, 80, 100, 120, 128, 134, 142, 210 |
| abstract_inverted_index.vs. | 247, 252, 257, 263 |
| abstract_inverted_index.was | 62, 140 |
| abstract_inverted_index.who | 149, 160, 191 |
| abstract_inverted_index.(17% | 246 |
| abstract_inverted_index.4.72 | 184 |
| abstract_inverted_index.5.28 | 182 |
| abstract_inverted_index.ALBI | 67, 124, 205, 223, 237, 267, 289 |
| abstract_inverted_index.HCC. | 84, 189 |
| abstract_inverted_index.São | 114 |
| abstract_inverted_index.This | 90 |
| abstract_inverted_index.data | 118 |
| abstract_inverted_index.did. | 161 |
| abstract_inverted_index.even | 22 |
| abstract_inverted_index.from | 119 |
| abstract_inverted_index.last | 138, 143 |
| abstract_inverted_index.mean | 179 |
| abstract_inverted_index.need | 50 |
| abstract_inverted_index.over | 217 |
| abstract_inverted_index.risk | 55, 81, 216, 230, 274, 294 |
| abstract_inverted_index.than | 234 |
| abstract_inverted_index.this | 58 |
| abstract_inverted_index.time | 218 |
| abstract_inverted_index.used | 132 |
| abstract_inverted_index.were | 131, 165 |
| abstract_inverted_index.when | 241 |
| abstract_inverted_index.with | 27, 39, 75, 95, 126, 177, 222, 236, 266, 298 |
| abstract_inverted_index.year | 245 |
| abstract_inverted_index.(HCC) | 19 |
| abstract_inverted_index.(HCV) | 10 |
| abstract_inverted_index.2.27, | 281 |
| abstract_inverted_index.95%CI | 282 |
| abstract_inverted_index.DAAs. | 28 |
| abstract_inverted_index.after | 23 |
| abstract_inverted_index.based | 33 |
| abstract_inverted_index.cause | 15 |
| abstract_inverted_index.could | 78 |
| abstract_inverted_index.first | 71, 121, 127, 211 |
| abstract_inverted_index.grade | 206, 224, 238, 268 |
| abstract_inverted_index.image | 146 |
| abstract_inverted_index.liver | 35 |
| abstract_inverted_index.lower | 196 |
| abstract_inverted_index.score | 68, 125, 290 |
| abstract_inverted_index.still | 11 |
| abstract_inverted_index.study | 91 |
| abstract_inverted_index.tests | 130 |
| abstract_inverted_index.there | 47 |
| abstract_inverted_index.those | 159 |
| abstract_inverted_index.tools | 52 |
| abstract_inverted_index.units | 102 |
| abstract_inverted_index.using | 167 |
| abstract_inverted_index.virus | 9 |
| abstract_inverted_index.years | 250, 255, 261 |
| abstract_inverted_index.(29.3% | 251 |
| abstract_inverted_index.(40.9% | 256 |
| abstract_inverted_index.(47.4% | 262 |
| abstract_inverted_index.21.4%) | 258 |
| abstract_inverted_index.8.2%), | 248 |
| abstract_inverted_index.During | 175 |
| abstract_inverted_index.Jamovi | 168 |
| abstract_inverted_index.Paulo, | 115 |
| abstract_inverted_index.assess | 64 |
| abstract_inverted_index.during | 278 |
| abstract_inverted_index.higher | 202, 229, 273 |
| abstract_inverted_index.values | 198 |
| abstract_inverted_index.years, | 185 |
| abstract_inverted_index.15.4%), | 253 |
| abstract_inverted_index.2.3.23. | 171 |
| abstract_inverted_index.23.9%). | 264 |
| abstract_inverted_index.Brazil, | 21 |
| abstract_inverted_index.Brazil. | 116 |
| abstract_inverted_index.Results | 172 |
| abstract_inverted_index.albumin | 197 |
| abstract_inverted_index.develop | 152 |
| abstract_inverted_index.improve | 54, 292 |
| abstract_inverted_index.leading | 14 |
| abstract_inverted_index.version | 170 |
| abstract_inverted_index.whereby | 37 |
| abstract_inverted_index.whether | 65 |
| abstract_inverted_index.Clinical | 117 |
| abstract_inverted_index.Conflict | 0 |
| abstract_inverted_index.Hospital | 104 |
| abstract_inverted_index.Medicina | 110 |
| abstract_inverted_index.Methods: | 89 |
| abstract_inverted_index.Patients | 85, 190, 265 |
| abstract_inverted_index.advanced | 40 |
| abstract_inverted_index.analyses | 164 |
| abstract_inverted_index.assessed | 242 |
| abstract_inverted_index.baseline | 288 |
| abstract_inverted_index.duration | 180 |
| abstract_inverted_index.fibrosis | 41 |
| abstract_inverted_index.included | 92 |
| abstract_inverted_index.patients | 38, 74, 94, 148, 187, 221, 235, 297 |
| abstract_inverted_index.software | 169 |
| abstract_inverted_index.stratify | 79 |
| abstract_inverted_index.suitable | 43 |
| abstract_inverted_index.two-fold | 272 |
| abstract_inverted_index.(p=0.019) | 240 |
| abstract_inverted_index.(p=0.036) | 208 |
| abstract_inverted_index.(p=0.039) | 199 |
| abstract_inverted_index.Clínicas | 106 |
| abstract_inverted_index.Faculdade | 108 |
| abstract_inverted_index.Hepatitis | 7 |
| abstract_inverted_index.Materials | 87 |
| abstract_inverted_index.analysis. | 136 |
| abstract_inverted_index.carcinoma | 18 |
| abstract_inverted_index.cirrhosis | 77, 97 |
| abstract_inverted_index.developed | 188, 192 |
| abstract_inverted_index.diagnosis | 157 |
| abstract_inverted_index.evaluated | 98 |
| abstract_inverted_index.fibrosis, | 36 |
| abstract_inverted_index.follow-up | 139, 279 |
| abstract_inverted_index.interest: | 2 |
| abstract_inverted_index.p=0.023). | 284 |
| abstract_inverted_index.performed | 69, 166 |
| abstract_inverted_index.screening | 145 |
| abstract_inverted_index.1.12-4.59, | 283 |
| abstract_inverted_index.Assessment | 286 |
| abstract_inverted_index.Evaluating | 214 |
| abstract_inverted_index.Therefore, | 46 |
| abstract_inverted_index.cirrhosis. | 300 |
| abstract_inverted_index.developing | 83, 232, 276 |
| abstract_inverted_index.evaluation | 72, 122 |
| abstract_inverted_index.follow-up, | 176 |
| abstract_inverted_index.laboratory | 129 |
| abstract_inverted_index.outpatient | 101, 212 |
| abstract_inverted_index.proportion | 203 |
| abstract_inverted_index.screening. | 45 |
| abstract_inverted_index.treatments | 26 |
| abstract_inverted_index.Discussion: | 174 |
| abstract_inverted_index.HCV-related | 76, 96, 299 |
| abstract_inverted_index.Objectives: | 6 |
| abstract_inverted_index.assessment. | 213 |
| abstract_inverted_index.population. | 59 |
| abstract_inverted_index.recommended | 32 |
| abstract_inverted_index.statistical | 135, 163 |
| abstract_inverted_index.Conclusions: | 285 |
| abstract_inverted_index.Introduction | 4 |
| abstract_inverted_index.Universidade | 112 |
| abstract_inverted_index.surveillance | 30 |
| abstract_inverted_index.Kaplan-Meier, | 220 |
| abstract_inverted_index.significantly | 195, 228 |
| abstract_inverted_index.hepatocellular | 17 |
| abstract_inverted_index.stratification | 56, 295 |
| cited_by_percentile_year | |
| countries_distinct_count | 0 |
| institutions_distinct_count | 9 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.4300000071525574 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.39966163 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |